Ixazomib

Ixazomib FDA approved ixazomib (NINLARO, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Ixazomib is the first approved oral proteasome inhibitor. November 20, 2015. More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm473804.htm

Drug Information Update – FDA approves new oral medication to treat multiple myeloma

Drug Information Update – FDA approves new oral medication to treat multiple myeloma FDA Division of Drug Information: Know the Moment It Happens The Division of Drug Information (DDI) is CDER’s focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA. Today theContinue reading “Drug Information Update – FDA approves new oral medication to treat multiple myeloma”